Loading…
No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers
The effect of rosuvastatin on the pharmacokinetics of digoxin was assessed in 18 healthy male volunteers in this double‐blind, randomized, two‐way crossover trial. Volunteers were dosed with rosuvastatin (40 mg once daily) or placebo to steady state before being given a single dose of digoxin 0.5 mg...
Saved in:
Published in: | Journal of clinical pharmacology 2002-12, Vol.42 (12), p.1352-1357 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3 |
---|---|
cites | cdi_FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3 |
container_end_page | 1357 |
container_issue | 12 |
container_start_page | 1352 |
container_title | Journal of clinical pharmacology |
container_volume | 42 |
creator | Martin, Paul D. Kemp, John Dane, Aaron L. Warwick, Mike J. Schneck, Dennis W. |
description | The effect of rosuvastatin on the pharmacokinetics of digoxin was assessed in 18 healthy male volunteers in this double‐blind, randomized, two‐way crossover trial. Volunteers were dosed with rosuvastatin (40 mg once daily) or placebo to steady state before being given a single dose of digoxin 0.5 mg. Blood and urine samples for the measurement of serum and urine digoxin concentrations were collected up to 96 hours following dosing. The effect of rosuvastatin was assessed by constructing 90% confidence intervals (CIs) around the treatment ratios (rosuvastatin + digoxin/placebo + digoxin) for digoxin exposure. The geometric least square mean AUC0‐t and Cmax of digoxin were only 4% higher when the drug was coadministered with rosuvastatin compared to placebo. The 90% CIs for both treatment ratios (AUC0‐t = 0.88‐1.24; Cmax = 0.89‐1.22) fell within the prespecified margin of 0.74 to 1.35; therefore, no significant pharmacokinetic interaction occurred between rosuvastatin and digoxin. The geometric mean amount of digoxin excreted into the urine and its renal clearance were similar with rosuvastatin and placebo. These results demonstrate that rosuvastatin has no effect on the pharmacokinetics of digoxin. Coadministration of rosuvastatin and digoxin was well tolerated. |
doi_str_mv | 10.1177/0091270002042012008 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_235858399</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>257967071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3</originalsourceid><addsrcrecordid>eNqNkF1v0zAUhi0EYmXwC5BQhMRl4PgjsXOJurEySpmmApeW6x7TrGk8bIet_x6HVuyGCyRLlqznOe_xS8hLCm8plfIdQEOZBAAGggFlAOoRmdCqYqWoQTwmk5EoR-SEPIvxBoDWoqJPyQllouaSw4RcL3xx7hzaVHhXXPs4_DIxmdT2he-LtMHiamPCzli_bXtMrY0jd9b-8PcZyWeGpkubffHNd0OfEEN8Tp4400V8cbxPydcP58vprJx_ufg4fT8vbUWbplwLK62zwEEgOMOMdAw5NhVS1sBq_BRXtmFNvVb1igq2drZSKBTUVHG0_JS8Psy9Df7ngDHpGz-EPkdqxitVKd40GeIHyAYfY0Cnb0O7M2GvKeixRv2PGrP16jh6WO1w_eAce8vAmyNgojWdC6a3bXzgBJesFmO8OHB3vku5m2033GHQmz-l5WgAkaPLHMrGZCjHp1FTR63tcP8_K-vL6dVMKJ7V8qC2MeH9X9WEra4ll5X-vrjQn5Z0cfl5OdeS_wZzdqbW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>235858399</pqid></control><display><type>article</type><title>No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Martin, Paul D. ; Kemp, John ; Dane, Aaron L. ; Warwick, Mike J. ; Schneck, Dennis W.</creator><creatorcontrib>Martin, Paul D. ; Kemp, John ; Dane, Aaron L. ; Warwick, Mike J. ; Schneck, Dennis W.</creatorcontrib><description>The effect of rosuvastatin on the pharmacokinetics of digoxin was assessed in 18 healthy male volunteers in this double‐blind, randomized, two‐way crossover trial. Volunteers were dosed with rosuvastatin (40 mg once daily) or placebo to steady state before being given a single dose of digoxin 0.5 mg. Blood and urine samples for the measurement of serum and urine digoxin concentrations were collected up to 96 hours following dosing. The effect of rosuvastatin was assessed by constructing 90% confidence intervals (CIs) around the treatment ratios (rosuvastatin + digoxin/placebo + digoxin) for digoxin exposure. The geometric least square mean AUC0‐t and Cmax of digoxin were only 4% higher when the drug was coadministered with rosuvastatin compared to placebo. The 90% CIs for both treatment ratios (AUC0‐t = 0.88‐1.24; Cmax = 0.89‐1.22) fell within the prespecified margin of 0.74 to 1.35; therefore, no significant pharmacokinetic interaction occurred between rosuvastatin and digoxin. The geometric mean amount of digoxin excreted into the urine and its renal clearance were similar with rosuvastatin and placebo. These results demonstrate that rosuvastatin has no effect on the pharmacokinetics of digoxin. Coadministration of rosuvastatin and digoxin was well tolerated.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1177/0091270002042012008</identifier><identifier>PMID: 12463730</identifier><identifier>CODEN: JCPCBR</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Area Under Curve ; Biological and medical sciences ; Cardiotonic agents ; Cardiovascular system ; Cross-Over Studies ; Digoxin - pharmacokinetics ; Double-Blind Method ; Drug Administration Schedule ; Drug Interactions ; Fluorobenzenes - blood ; Fluorobenzenes - pharmacology ; Fluorobenzenes - urine ; General and cellular metabolism. Vitamins ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - urine ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pyrimidines ; Rosuvastatin Calcium ; Sulfonamides ; Time Factors</subject><ispartof>Journal of clinical pharmacology, 2002-12, Vol.42 (12), p.1352-1357</ispartof><rights>2002 American College of Clinical Pharmacology</rights><rights>2002 SAGE Publications</rights><rights>2003 INIST-CNRS</rights><rights>Copyright SAGE PUBLICATIONS, INC. Dec 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3</citedby><cites>FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14372649$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12463730$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martin, Paul D.</creatorcontrib><creatorcontrib>Kemp, John</creatorcontrib><creatorcontrib>Dane, Aaron L.</creatorcontrib><creatorcontrib>Warwick, Mike J.</creatorcontrib><creatorcontrib>Schneck, Dennis W.</creatorcontrib><title>No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>The effect of rosuvastatin on the pharmacokinetics of digoxin was assessed in 18 healthy male volunteers in this double‐blind, randomized, two‐way crossover trial. Volunteers were dosed with rosuvastatin (40 mg once daily) or placebo to steady state before being given a single dose of digoxin 0.5 mg. Blood and urine samples for the measurement of serum and urine digoxin concentrations were collected up to 96 hours following dosing. The effect of rosuvastatin was assessed by constructing 90% confidence intervals (CIs) around the treatment ratios (rosuvastatin + digoxin/placebo + digoxin) for digoxin exposure. The geometric least square mean AUC0‐t and Cmax of digoxin were only 4% higher when the drug was coadministered with rosuvastatin compared to placebo. The 90% CIs for both treatment ratios (AUC0‐t = 0.88‐1.24; Cmax = 0.89‐1.22) fell within the prespecified margin of 0.74 to 1.35; therefore, no significant pharmacokinetic interaction occurred between rosuvastatin and digoxin. The geometric mean amount of digoxin excreted into the urine and its renal clearance were similar with rosuvastatin and placebo. These results demonstrate that rosuvastatin has no effect on the pharmacokinetics of digoxin. Coadministration of rosuvastatin and digoxin was well tolerated.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Cardiotonic agents</subject><subject>Cardiovascular system</subject><subject>Cross-Over Studies</subject><subject>Digoxin - pharmacokinetics</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug Interactions</subject><subject>Fluorobenzenes - blood</subject><subject>Fluorobenzenes - pharmacology</subject><subject>Fluorobenzenes - urine</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - urine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrimidines</subject><subject>Rosuvastatin Calcium</subject><subject>Sulfonamides</subject><subject>Time Factors</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqNkF1v0zAUhi0EYmXwC5BQhMRl4PgjsXOJurEySpmmApeW6x7TrGk8bIet_x6HVuyGCyRLlqznOe_xS8hLCm8plfIdQEOZBAAGggFlAOoRmdCqYqWoQTwmk5EoR-SEPIvxBoDWoqJPyQllouaSw4RcL3xx7hzaVHhXXPs4_DIxmdT2he-LtMHiamPCzli_bXtMrY0jd9b-8PcZyWeGpkubffHNd0OfEEN8Tp4400V8cbxPydcP58vprJx_ufg4fT8vbUWbplwLK62zwEEgOMOMdAw5NhVS1sBq_BRXtmFNvVb1igq2drZSKBTUVHG0_JS8Psy9Df7ngDHpGz-EPkdqxitVKd40GeIHyAYfY0Cnb0O7M2GvKeixRv2PGrP16jh6WO1w_eAce8vAmyNgojWdC6a3bXzgBJesFmO8OHB3vku5m2033GHQmz-l5WgAkaPLHMrGZCjHp1FTR63tcP8_K-vL6dVMKJ7V8qC2MeH9X9WEra4ll5X-vrjQn5Z0cfl5OdeS_wZzdqbW</recordid><startdate>200212</startdate><enddate>200212</enddate><creator>Martin, Paul D.</creator><creator>Kemp, John</creator><creator>Dane, Aaron L.</creator><creator>Warwick, Mike J.</creator><creator>Schneck, Dennis W.</creator><general>Blackwell Publishing Ltd</general><general>SAGE Publications</general><general>Sage Science</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>200212</creationdate><title>No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers</title><author>Martin, Paul D. ; Kemp, John ; Dane, Aaron L. ; Warwick, Mike J. ; Schneck, Dennis W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Cardiotonic agents</topic><topic>Cardiovascular system</topic><topic>Cross-Over Studies</topic><topic>Digoxin - pharmacokinetics</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug Interactions</topic><topic>Fluorobenzenes - blood</topic><topic>Fluorobenzenes - pharmacology</topic><topic>Fluorobenzenes - urine</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - urine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrimidines</topic><topic>Rosuvastatin Calcium</topic><topic>Sulfonamides</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martin, Paul D.</creatorcontrib><creatorcontrib>Kemp, John</creatorcontrib><creatorcontrib>Dane, Aaron L.</creatorcontrib><creatorcontrib>Warwick, Mike J.</creatorcontrib><creatorcontrib>Schneck, Dennis W.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martin, Paul D.</au><au>Kemp, John</au><au>Dane, Aaron L.</au><au>Warwick, Mike J.</au><au>Schneck, Dennis W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2002-12</date><risdate>2002</risdate><volume>42</volume><issue>12</issue><spage>1352</spage><epage>1357</epage><pages>1352-1357</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><coden>JCPCBR</coden><abstract>The effect of rosuvastatin on the pharmacokinetics of digoxin was assessed in 18 healthy male volunteers in this double‐blind, randomized, two‐way crossover trial. Volunteers were dosed with rosuvastatin (40 mg once daily) or placebo to steady state before being given a single dose of digoxin 0.5 mg. Blood and urine samples for the measurement of serum and urine digoxin concentrations were collected up to 96 hours following dosing. The effect of rosuvastatin was assessed by constructing 90% confidence intervals (CIs) around the treatment ratios (rosuvastatin + digoxin/placebo + digoxin) for digoxin exposure. The geometric least square mean AUC0‐t and Cmax of digoxin were only 4% higher when the drug was coadministered with rosuvastatin compared to placebo. The 90% CIs for both treatment ratios (AUC0‐t = 0.88‐1.24; Cmax = 0.89‐1.22) fell within the prespecified margin of 0.74 to 1.35; therefore, no significant pharmacokinetic interaction occurred between rosuvastatin and digoxin. The geometric mean amount of digoxin excreted into the urine and its renal clearance were similar with rosuvastatin and placebo. These results demonstrate that rosuvastatin has no effect on the pharmacokinetics of digoxin. Coadministration of rosuvastatin and digoxin was well tolerated.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>12463730</pmid><doi>10.1177/0091270002042012008</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0091-2700 |
ispartof | Journal of clinical pharmacology, 2002-12, Vol.42 (12), p.1352-1357 |
issn | 0091-2700 1552-4604 |
language | eng |
recordid | cdi_proquest_journals_235858399 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Adolescent Adult Area Under Curve Biological and medical sciences Cardiotonic agents Cardiovascular system Cross-Over Studies Digoxin - pharmacokinetics Double-Blind Method Drug Administration Schedule Drug Interactions Fluorobenzenes - blood Fluorobenzenes - pharmacology Fluorobenzenes - urine General and cellular metabolism. Vitamins Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors - urine Male Medical sciences Middle Aged Pharmacology. Drug treatments Pyrimidines Rosuvastatin Calcium Sulfonamides Time Factors |
title | No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T21%3A01%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20Effect%20of%20Rosuvastatin%20on%20the%20Pharmacokinetics%20of%20Digoxin%20in%20Healthy%20Volunteers&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Martin,%20Paul%20D.&rft.date=2002-12&rft.volume=42&rft.issue=12&rft.spage=1352&rft.epage=1357&rft.pages=1352-1357&rft.issn=0091-2700&rft.eissn=1552-4604&rft.coden=JCPCBR&rft_id=info:doi/10.1177/0091270002042012008&rft_dat=%3Cproquest_cross%3E257967071%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5199-d4c7cfc0304e0fa2a7f2e3e95e1290b204238c9296d86b142dfc58e4806183ec3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=235858399&rft_id=info:pmid/12463730&rfr_iscdi=true |